.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01G_AminoglycosideAntibacterials.J01GB01_Tobramycin.Tobramycin

Information

Tobramycin is an aminoglycoside antibiotic primarily used for the treatment of serious bacterial infections caused by Gram-negative organisms, including Pseudomonas aeruginosa. It is commonly used in hospital settings for infections such as bacteremia, respiratory tract infections, urinary tract infections, and is also used in inhalation form for cystic fibrosis. Tobramycin is an approved drug and remains in current clinical use.

Pharmacokinetics

Pharmacokinetic parameters from healthy adults after intravenous administration of tobramycin.

References

1. Sullins, AK, & Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatric drugs 15(2) 93–117. DOI:10.1007/s40272-013-0017-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23529866

2. Praet, A, et al., & Goutelle, S (2021). Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis. Antimicrobial agents and chemotherapy 65(10) e0073721–None. DOI:10.1128/AAC.00737-21 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34280011

3. Bloomfield, C, et al., & Hennig, S (2016). Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients. Antimicrobial agents and chemotherapy 60(6) 3407–3414. DOI:10.1128/AAC.02654-15 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27001806

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)